MAPT and dementia: The confirmatory TRAILBLAZER-ALZ2 Phase 3 RCT (NCT04437511) enrolled 1736 participants with MCI/mild dementia due to AD who were amyloid PET-positive (68 % with low-medium tau PET uptake, 32 % with high tau PET) [3].